SPONSORED CONTENT
Covered entities participating in the 340B program continue to operate in an environment of increasing complexity and scrutiny. As regulatory expectations evolve, one area that has emerged as a critical point of vulnerability is referral documentation. While
…SPONSORED CONTENT
In fiscal year 2025, the Health Resources and Services Administration (HRSA) audited 115 covered entities — and 49% received adverse findings. In other words, nearly one in two programs had a 340B compliance issue last year.
While this is an improvement
…
Q: Tell us some interesting details about your company’s history.
At RxParadigm, we like to think we’ve always been a few steps ahead, not because we have a crystal
…SPONSORED CONTENT
Medicare’s Maximum Fair Price (MFP) went into effect on January 1, introducing negotiated pricing for select Medicare Part D drugs under the Inflation Reduction Act (IRA). An additional 15 drugs are expected to follow in 2027 and beyond.
As a Third-Party
…SPONSORED CONTENT
Uncertainty has become a constant in the 340B landscape. Legal challenges, shifting manufacturer policies, and evolving oversight have made one thing clear: waiting for definitive answers before taking action is no longer a viable strategy.
For covered entity leaders, the
Q: What is the primary problem 340B Referral Compass solves?
Referral Compass helps covered entities (CEs) address one of the most difficult and often underdeveloped areas…
Read More »SPONSORED CONTENT
Despite a number of state laws protecting 340B covered entities (CEs) access to contract pharmacies, lawsuits by manufacturers, court decisions, and pending appeals create significant uncertainty for these entities. These contract pharmacy restrictions can limit access to important 340B medications and
…SPONSORED CONTENT
There has been no formal announcement explaining how the Inflation Reduction Act (IRA) is playing out operationally within 340B.
Instead, it’s showing up in the data. For many organizations, it looks subtle at first. A dip in qualified claims. A shift in
…SPONSORED CONTENT
Q1 2026 started rougher than predicted for 340B programs. Ceiling prices compressed. Penny pricing disappeared on drugs that used to be your biggest savings. And an entire drug category that looked like a growth engine 12 months ago went dark almost
…
Q: What is the primary problem Pillr One solves?
340B programs are increasingly difficult to manage across fragmented systems that handle mixed-use, central distribution, contract…
Read More »
